Matthew Galsky Discusses Treatment for Lymph Node-Positive Bladder Cancer
Matthew Galsky, MD, medical oncologist, Icahn School of Medicine at Mount Sinai, discusses treatment for lymph node-positive bladder cancer.
Matthew Galsky, MD, medical oncologist, Icahn School of Medicine at Mount Sinai, discusses treatment for lymph node-positive bladder cancer.
Using the National Cancer Data Base, Galsky identified a group of about 1700 patients with bladder cancer that spread to regional lymph nodes and looked at the different outcomes of the treatments they received. Patients were administered chemotherapy, surgery, chemotherapy and then surgery, or surgery and then chemotherapy.
Galsky found that the patients who received some combination of chemotherapy and surgery, regardless of sequence, had the highest 5-year survival rates. Findings from the study were presented at ASCO’s 2016 Annual Meeting.
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
April 20th 2024Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.
Maintenance Avelumab Has Similar Efficacy in Real World for Urothelial Cancer
March 5th 2024Patients with metastatic urothelial cancer treated with frontline maintenance therapy with avelumab following platinum-based chemotherapy in the real-world setting had similar outcomes as observed in the JAVELIN Bladder 100 trial.
Key Advances in Cancer Survivorship Toxicity Management
July 15th 2022In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
